ADELAIDE, Australia / RankWire.AI / – Researchers from Adelaide University and the Olivia Newton-John Cancer Research Institute have pinpointed a novel molecular switch that influences the progression of aggressive tumors. The discovery was published in EMBO Molecular Medicine and reveals an innovative strategy to address triple-negative breast cancer by restoring a key regulatory molecule called miR-342. This breakthrough paves the way for new methods to prevent deadly secondary cancers in organs such as the lungs and bones.
Although triple-negative breast cancer makes up 10% to 15% of the roughly 21,000 annual breast cancer cases in Australia, it accounts for a disproportionately high number of fatalities. This subtype is characterized by the absence of estrogen, progesterone, and HER2 receptors, which makes standard hormone-targeted therapies ineffective. The lead researchers showed that a decline in miR-342 causes the overactivation of a cancer-promoting pathway called E2F, which enables dormant cancer cells to spread and create dangerous secondary tumors throughout the body.
Potential for Diagnostic Biomarker Testing to Identify High-Risk Patients
In pre-clinical experiments, scientists found that increasing miR-342 levels significantly suppressed the dissemination of cancer cells to distant sites. Additionally, they observed that palbociclib, an approved CDK4/6 inhibitor used in treating hormone receptor-positive breast cancers, effectively hindered the growth of metastatic tumors in models with low miR-342 expression. These results indicate that assessing miR-342 levels could enable clinicians to repurpose existing drugs for high-risk patients.
Associate Professor Philip Gregory, co-senior author from the Centre for Cancer Biology at Adelaide University, confirmed that metastasis prevention remains the greatest hurdle in managing aggressive breast cancers. Gregory highlighted that because palbociclib targets the overactive E2F pathway, administering it after cancer spread occurs can prevent microscopic deposits from enlarging. This approach shifts focus from merely shrinking primary tumors to stopping microscopic secondary cancers from developing into fatal conditions.
miR-342 as a Central Regulatory Molecule for Cancer-Related Genes
The research team emphasized that the biological diversity of triple-negative breast cancer has historically posed challenges to creating universal targeted treatments. By identifying a specific vulnerability shared by a particular patient subgroup, their findings open the door to personalized therapies. As Australian scientists develop a promising new method to fight triple-negative breast cancer, efforts are underway to validate the results using patient-derived models prior to clinical testing.
Medical oncologists and cancer research bodies across Australia have expressed support for the new discoveries, stressing the critical need for expanded treatment options when standard therapies fall short. The team intends to collaborate with international clinical networks to speed up biomarker screening efforts. Confirming the utility of miR-342 testing could soon enable clinicians to identify suitable candidates for targeted CDK4/6 inhibitor therapies early in treatment.